LISA ULMER: Open Payments
NPI 1942349931 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,356 in 95 payments from 36 companies in 2025. Trend: 2023 $1,826 · 2024 $1,764 · 2025 $2,356
Food & beverage: $2,356
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 12 | $290 |
| Novartis Pharmaceuticals Corporation | 10 | $246 |
| Daiichi Sankyo Inc. | 5 | $128 |
| ABBVIE INC. | 5 | $126 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $117 |
| Celgene Corporation | 4 | $114 |
| Genentech USA, Inc. | 4 | $105 |
| GENZYME CORPORATION | 3 | $95 |
| Genmab U.S., Inc. | 3 | $85 |
| Incyte Corporation | 3 | $67 |
Products named: Enhertu, Nubeqa, REBLOZYL, SCEMBLIX, KISQALI, EPKINLY, RYBREVANT, ERLEADA.
Industry payments across PA — which companies pay providers there.
